EVP-ABD-enhanced MRI to evaluate diffuse liver disease in a rat model.
OBJECTIVE
To evaluate the feasibility of using manganese-based MR imaging contrast agent EVP-ABD to detect diffuse liver disease in an established rat hepatitis model.


METHODS
Hepatitis was induced by administration of CCl(4) in corn oil vehicle to rats intraperitoneally. MR images were acquired on a 3T scanner using a volume coil approximately 36 hours after the administration of CCl(4). EVP-ABD was administered via a tail vein at a dose of 10 mumol/kg. Multi-TI turboflash images were acquired to evaluate liver R1 (=1/T1) values before and after the EVP-ABD administration. Eighteen rats received various doses of CCl(4) and completed pre- and postcontrast MRI scans and liver histologic evaluation.


RESULTS
The liver R1 after the EVP-ABD administration and the change of the liver R1 before and after the administration, DeltaR1, show significant correlations with the CCl(4) dose. A significant correlation was also found between the histologic scores and the CCl(4) doses despite known variability in the relationship of CCl(4) dose to histology. A significant correlation was found between the histologic score and DeltaR1.


CONCLUSIONS
Our results indicate that EVP-ABD-enhanced MRI can detect diffuse liver disease generated by CCl(4) based on the significant correlation between proton R1 in liver following EVP-ABD and the CCl(4) doses as well as the histologic scores.
Zuo
Chun S
CS
Brain Imaging Center, McLean Hospital, Belmont, Massachusetts 02478, USA. chun@mclean.harvard.edu
Seoane
Peter R
PR
Thomsen
Morgane
M
Gillis
Tim
T
Meloni
Edward
E
Harnish
Phillip P
PP
Renshaw
Perry F
PF
D000818:Animals; D002251:Carbon Tetrachloride / Q000633:toxicity; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis*; D003287:Contrast Media / Q000008:administration & dosage*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005240:Feasibility Studies; D007089:Image Enhancement / Q000379:methods; D021621:Imaging, Three-Dimensional; D008099:Liver / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008345:Manganese; D051381:Rats; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index
D003287:Contrast Media; C472505:EVP-ABD; D008345:Manganese; D002251:Carbon Tetrachloride